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An inhibitor of fibroblast growth 
factor receptor-1 (FGFR1) promotes 
late-stage terminal differentiation 
from NGN3+ pancreatic endocrine 
progenitors
Yzumi Yamashita-Sugahara1, Masahito Matsumoto1, Manami Ohtaka2, Ken Nishimura3, 
Mahito Nakanishi2, Kohnosuke Mitani4 & Yasushi Okazaki1
Human induced pluripotent stem cells (hiPSCs) provide a potential resource for regenerative medicine. 
To identify the signalling pathway(s) contributing to the development of functional β cells, we 
established a tracing model consisting of dual knock-in hiPSCs (INS-Venus/NGN3-mCherry) (hIveNry) 
expressing the fluorescent proteins Venus and mCherry under the control of intrinsic insulin (INS) and 
neurogenin 3 (NGN3) promoters, respectively. hIveNry iPSCs differentiated into NGN3- and mCherry-
positive endocrine progenitors and then into Venus-positive β cells expressing INS, PDX1, NKX6.1, 
and glucokinase (GCK). Using these cells, we conducted high-throughput screening of chemicals and 
identified a specific kinase inhibitor of fibroblast growth factor receptor 1 (FGFR1) that acted in a stage-
dependent manner to promote the terminal differentiation of pancreatic endocrine cells, including 
β cells, from the intermediate stage of pancreatic endocrine progenitors while blocking the early 
development of pancreatic progenitors. This FGFR1 inhibitor augmented the expression of functional β 
cell markers (SLC30A8 and ABCC8) and improved glucose-stimulated INS secretion. Our findings indicate 
that the hIveNry model could provide further insights into the mechanisms of hiPS-derived β cell 
differentiation controlled by FGFR1-mediated regulatory pathways in a temporal-dependent fashion.
Type 1 diabetes is an autoimmune disease characterized by the complete loss of insulin (INS) due to the destruc-
tion of β cells, and its treatment is solely dependent on INS administration1. Although islet transplantation is a 
promising therapy for type 1 diabetes, difficulties in obtaining sufficient islets and immunosuppression problems 
point to the need for alternative cell sources for the generation of INS-expressing β cells2. Human induced pluri-
potent stem cells (hiPSCs) represent an important resource since they have the potential to differentiate into 
INS-producing functional β cells.
Fibroblast growth factor receptor 1 (FGFR1) signalling during embryonic development is crucial and the phe-
notype is lethal in null mice before or during gastrulation3,4. Several studies of mouse models have demonstrated 
the importance of FGFR1 for normal structural development, with FGFR1 mutations linked to Pfeiffer syndrome, 
which is characterized by abnormal cranial formation5,6. In pancreatic development, an FGFR1 agonist of FGF4 
signalling regulates the patterning of pancreatic and duodenal homeobox 1 (PDX1)-expressing foregut endoderm 
and pancreatic expansion7. Mice expressing dominant-negative FGFR1c driven by the PDX1 promoter develop 
age-specific diabetes8. Moreover, endogenous FGFR1 expression is regulated by PDX1 in β cells, while the expression 
of a dominant-negative PDX1 mutant inhibits FGFR1 expression leading to the downregulation of Glut28,9. Thus, 
positive feedback regulation via the FGFR1-PDX1 cascade causes the differentiation and maintenance of β cells.
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Many studies have reported the generation of pancreatic endocrine cells in vitro from human embryonic 
stem cells (hESCs)/hiPSCs. However, pancreatic β -like cells derived from the differentiation of stem cells 
in vitro exhibit a limited capacity for glucose-stimulated insulin secretion (GSIS), a hallmark of functionally 
mature β cells10–13. Recently, attempts at generating functional β cells from hESCs/hiPSCs in vitro produced 
PDX1-expressing (PDX1+ ) pancreatic progenitors (PPs) from definitive endoderm (DE) and maintained func-
tional β cells that featured similar expression profiles and glucose responsivity to primary human β cells under 
the control of FGFR1-mediated signalling14,15. According to the differentiation protocols used in these studies, 
FGFR1 or FGFR2 agonists are utilized to drive the PDX1 expression that is essential for the early stages of β cell 
differentiation in vitro. Therefore, these procedures have been developed mostly based on mimicking normal 
pancreatic development mediated by the transition from PDX1+ PPs to endocrine progenitors (EPs) transiently 
expressing neurogenin 3 (NGN3) as a master regulator of hormonal endocrine cells. V-Maf avian muscu-
loaponeurotic fibrosarcoma oncogene homolog A (MAFA), which is expressed together with PDX1 in adult β 
cells, is critical during the maturation of functional β cells in adult islets. Although the mode of action of FGFs 
at the early transition from DE to the PDX1+ PP stage is relatively well defined by genetic ablation studies, the 
regulatory role of FGFR-mediated signalling in the terminal differentiation and maturation processes of hiPSCs 
-derived β cells and their differentiation instability remains unclear.
To clarify the unresolved issues outlined above, we established a dual fluorescence reporter system using 
mCherry and Venus to trace the transition of hiPS-derived NGN3+ EP cells to terminally differentiated β cells. 
The tracing model was designed to facilitate a better understanding of the developmental signals that contribute 
to the intermediate and terminal differentiation of EPs and lead to the maturation of β cells. Using this reporter 
system, we have discovered that inhibition of FGFR1-mediated signalling not only enhances the efficiency of 
endocrine cell intermediate and terminal differentiation, but also improves GSIS while additionally increasing 
the expression of functional β cell markers. Herein, we propose that blockade of the FGFR1-mediated signalling 
cascade contributes to the efficient intermediate and terminal differentiation of β cells and the subsequent early 
PDX1+ PP stage that is essential for the temporal-dependent action of FGFs and the production of functional β 
cells responsible for the maintenance of glucose homeostasis.
Results
Gene targeting at the INS and NGN3 loci in hiPSCs. It has been reported previously that hESCs/hiP-
SCs have a propensity to differentiate towards certain lineages16,17 and we tested the ability of the hiPSCs to dif-
ferentiate into pancreatic endoderm lineages (Fig. S1)10. We examined the differentiation efficiency of 246H1 and 
TIG3/KOSM #7 (TIG) hiPSC lines reprogrammed with OCT4/SOX2/KLF4/Myc via retrovirus and Sendai virus, 
respectively. Following treatment with activin A and Wnt3a, the mRNA expression of markers of DE (CXCR4 
and CER1) and mesendoderm (Brachyury) were higher in TIG hiPSCs than in 246H1 hiPSCs from days 1 to 5. 
Pluripotency markers (OCT3/4 and NANOG) were also higher in TIG hiPSCs than in 246H1 hiPSCs during this 
early period, but were not detected on days 9 and 15. Therefore, we chose the TIG hiPSCs for the construction 
of knock-in (KI) reporter cells since this line appears to be highly sensitive to mediators of pancreatic β cell 
differentiation.
We constructed a helper-dependent adenovirus targeting vector (HDAdV) to generate KI hiPSCs that marks 
INS-producing cells with the green fluorescent protein Venus (INS-Venus) (Fig. 1A). TIG hiPSCs were infected 
with adenoviral particles packed with INS-Venus-PGKneo HDAdV, and drug-resistant clones were analysed by 
Southern blotting to determine gene-targeted clones (Fig. 1B). The parental TIG (wt) and three selected clones 
(#6, 9, and 17) are shown with the wild-type INS allele displaying a 20.9-kb band on BstXI-digested DNA using 
a 5i or 3o probe (Fig. 1A,B, probes a and c) and the INS-Venus KI locus showing a 9.9-kb band with a 5V probe 
and a 13.1-kb band with a 3′ probe (Fig. 1B, KI). Among the three KI clones (#6, 9, and 17), one (#9) was chosen 
to generate the dual KI (DKI) clones expressing the red fluorescent protein mCherry driven by the neurogenin 3 
(NGN3) promoter (NGN3-mCherry) (Fig. 1C). Southern blot analysis indicated that homologous recombination 
in the five representative clones (#9–3, 9–11, 9–15, 9–16, and 9–35) occurred properly and efficiently using the 
NGN3-mCherry HDAdV system, based on the detection of 14.0-kb and 12.9-kb bands following digestion of 
genomic DNA with AccI (Ac)/AgeI (Ag) using the 5′ , mCherry, and 3 probes (Fig. 1C,D, probes a, b, and c, respec-
tively). The DKI clones we established above are herein termed hiPS/INS-Venus/NGN3-mCherry (hIveNry) cells.
Tracing the differentiation of hIveNry DKI cells into pancreatic endocrine lineages. To test the 
potential of DKI hiPSC clones to differentiate into pancreatic β cells, we used a previously reported protocol to 
produce NGN3+ EP and INS-producing cells with high efficiency (Takeda’s protocol, Fig. S2A)13. Takeda’s proto-
col consists of three steps: differentiation of hiPSCs to DE by treatment with CHIR and activin A (days 1–3, stage 
1); production of PPs by treatment with dorsomorphin, retinoic acid (RA), and SB431542 (days 3–10, stage 2); 
and differentiation into endocrine cells by treatment with forskolin (Fsk), dexamethasone (Dex), nicotinamide 
(Nico), and an Alk5 inhibitor (days 11–21, stage 3). We observed mCherry-positive (mCherry+ ) cells in each 
of the three hIveNry DKI clones (#9–3, 9–11, and 9–15) just after the appearance of PPs (early in stage 3, around 
day 11), and the number of mCherry+ cells was augmented at day 14 as visualized under a microscope (Fig. 2A). 
Furthermore, a small number of Venus-positive (Venus+ ) cells could also be detected. mCherry+ and Venus+ 
cells were counted and, as shown in Fig. 2A (right panel), there were more Venus+ cells on day 21 than on day 14 
(Supplementary Video). In Fig. 2B, immunofluorescence analysis shows the parental #9 hiPSCs (INS-Venus KI 
hiPSCs) and DKI hiPSCs derived from the #9 cells, named #9–3 and #9–15; on day 3 of differentiation, we could 
detect the expression of SOX17, which is a marker of DE. Moreover, on day 21, we could detect INS, a marker 
of β cells, glucagon (GCG), a marker of alpha cells, and somatostatin (SST), a marker of δ cells. Some of the 
double-stained cells co-expressed INS and GCG or INS and SST, indicating immature pancreatic β cells (Fig. 2B).
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The Venus KI hiPSCs (#9) and their clones displayed similar potential for differentiation. The mRNA levels 
of the pluripotency markers OCT3/4 and NANOG were high in hiPSCs prior to induction at day 0, decreased 
sharply by day 3, and were undetectable on days 10 and 21 (Fig. 2C). mRNA for the endocrine markers INS, GCG, 
and SST was detectable on day 21, but not on days 0 or 10, indicating that all DKI hIveNry clones are capable of 
Figure 1. Gene targeting at the INS and NGN3 loci in hiPSCs. (A) Schematic illustration of INS knockout 
with HDAdV. The structures of the targeting vector (HDAdV-INS-Ve-pGK-Neo), the wild-type human INS 
locus, and the targeted locus are shown. Venus cDNA was inserted under the INS promoter at the ATG of the 
coding region (at exon 2; exons are shown as grey boxes and numbered 1–3). Venus cDNA: the expression 
cassette for Venus (yellow fluorescent protein gene). HSVtk: the herpes simplex virus thymidine kinase gene 
cassette. BstXl sites (B) are indicated; probes a, b, and c indicate the 5′ probe, Venus probe, and 3′ probe used 
for Southern blotting analysis, respectively. (B) The targeted hiPSC clones (#6, 9, and 17) were analysed by 
Southern blotting with the 5′ probe (a) (9.9 kb), Venus probe (b) (9.9 kb), and 3′ probe (13.1 kb). (C) To target 
NGN3-mCherry, we chose clone #9 of the INS-Venus-targeted hiPSCs. The structure of the targeting vector 
for NGN3-mCherry (HDAdV-NGN3-mcherry-pGK-puro) is shown. mCherry cDNA was inserted under 
the control of the NGN3 promoter at ATG of the coding region (at exon 2; exons are shown as grey boxes 
numbered 1 and 2). AccI (Ac) and AgeI (Ag) sites are indicated, and probes a, b, and c indicate the 5t probe, 
mCherry probe, and 3p probe used for Southern blotting analysis, respectively. (D) The targeted hiPSC clones 
(#9–3, 9–11, 9–15, 9–16, and 9–35) were analysed by Southern blotting analysis with the 5′ probe (a) (14.0 kb), 
mCherry probe (b) (14.0 kb), and 3′ probe (c) (12.9 kb). Uncropped versions of the scans are presented in 
Supplementary Fig. S6. HDAdV: helper-dependent adenoviral vector.
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differentiating into α , β , and δ cells (Fig. 2D) and also into pancreatic polypeptide-expressing and ghrelin-positive 
ε cells (data not shown). The PP marker PDX1 was also upregulated on day 10 during the early PP stage and termi-
nal late-stage on day 21. The transient expression pattern of the EP marker NGN3 in clones #9–15 and #9–35 was 
also strikingly similar to the normal development of NGN3+ EPs in vivo (Fig. 2D). Co-staining of the INS and 
C-peptide matched fully and the expression of INS and Venus coincided, indicating that the Venus-expressing 
cells could be monitored as INS-positive (INS+ ) cells (Fig. 3A). Furthermore, immunostaining analysis revealed 
Figure 2. DKI INS-Venus/NGN3-mCherry hiPSC (hIveNry) clones can differentiate into pancreatic 
endocrine cells. (A) hIveNry cells were differentiated towards pancreatic β cells and analysed by in vivo  
imaging on days 14 and 21 of differentiation. The graph shows the reporter-positive cells at the indicated days. 
(B) hIveNry cells were analysed by immunofluorescence on day 3 for the expression of the definitive endoderm 
marker SOX17 and, on day 21, the final differentiation day, for the co-expression of INS and GCG or INS 
and SST. mRNA expression analysis of hIveNry clones on days 0, 3, 10, and 21 of differentiation shows the 
pluripotency markers OCT3/4 and NANOG (C) and the endocrine markers INS, SST, GCG, PDX1, and NGN3 
(D). d: day; SOX17: sex-determining region Y (SRY) box 17. Scale bar, 100 μ m.
www.nature.com/scientificreports/
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that mCherry+ cells coincided with NGN3-expressing EP cells (Fig. 3A). To characterize insulin-producing and 
other endocrine cells generated by this protocol, we examined the expression of some of the beta cell lineage 
markers, such as PDX1 and CHGB. As shown in Fig. 3B, PDX1 and CHGB were expressed with INS in most cells, 
but PDX1 was also expressed with SST in some of the cells. In addition, CHGB was additionally expressed in 
other types of cells not expressing INS (Fig. 3B). Together, these results indicate that several hIveNry DKI clones 
(#9–3, 9–11, 9–15, 9–16, and 9–35) could be used to trace the terminal differentiation of the β cell lineage from 
mCherry+ EP cells (EPs).
Analysis of Venus+ and mCherry+ EP cells. As reported, the efficiency of differentiation into pan-
creatic β cells from hiPSCs is approximately 10% from INS-producing cells13. Therefore, it is desirable to profile 
each group of fluorescent cells to view their differentiation state. To profile each group of fluorescence-positive 
cells, differentiated hIveNry cells were sorted on day 21. Venus+ cells, mCherry+ cells, and fraction of cells with 
no fluorescence (as a negative control) (Fig. 4A) were characterized by analysing the mRNA levels of several 
endocrine markers (Fig. 4B). Importantly, Venus+ cells were highly enriched for markers of the β cell lineage, 
such as INS, PDX1, GLP1R, and MAFA, in addition to GCG and SST. By contrast, mCherry+ PE cells were more 
enriched for NGN3 than Venus+ -sorted cells (Fig. 4B), in accordance with a mutually exclusive relationship 
between NGN3 and PDX118,19 (Fig. S4B). Although Takeda’s protocol is incapable of producing mature β cells 
from iPSCs and some of the INS+ cells represent immature polyhormonal cells, we found that the sorted Venus+ 
cells co-expressed GCG and SST together with INS. Also, we observed that both mCherry+ - and Venus+ -sorted 
cells expressed NKX6.1, a progenitor marker that is also expressed in mature β cells14,15. These data provide a 
strong rationale for investigating Venus+ and mCherry+ cells as potential EP and INS-producing cells for their 
utility in elucidating the mechanisms of β cell differentiation from hiPSCs.
Figure 3. Expression of the fluorescent marker proteins Venus and mCherry coincides with INS and 
NGN3 expression, respectively. One of the hiPSC clones (#9–15) was selected for immunostaining analysis 
after differentiation into pancreatic endocrine cells. (A) Venus and INS proteins were detected on day 21 with 
an anti-GFP antibody and anti-INS antibody, respectively. A magnified image of the INS and Venus double-
stained cells is shown. mCherry protein was detected with an anti-RFP antibody and co-stained with an 
anti-NGN3 antibody on day 15. INS expression was analysed with an anti-INS antibody and anti-C-peptide 
antibody to view the coincidence of INS expression (days 21 and 17). Co-staining of mCherry with GCG, 
mCherry with SST, and mCherry with C-peptide was analysed. (B) On the final day of differentiation (21 days), 
immunostaining was performed for other markers, namely, PDX1 with INS, PDX1 with SST and INS with 
CHGB. Scale bar, 100 μ m in A and 25 μ m for B.
www.nature.com/scientificreports/
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Figure 4. Differentiated DKI hIveNry #9–15 Venus-expressing cells are polyhormonal β cells. DKI hIveNry 
(clone #9–15) hiPSCs were differentiated into pancreatic β cells. Venus+ cells, mCherry+ cells (mche), 
and negative control (NC) cells were sorted with a cell sorter (SH800Z), and the mRNA expression levels 
of each fraction of cells were analysed to characterize the differentiated cells. (A) The live cell picture shows 
differentiated β cells before sorting at 21 days of differentiation, with Venus+ and mCherry+ and double-
positive cells evident in the clusters. Gating of Venus and mCherry for sorting. The left picture indicates the 
negative cells that do not express the reporter genes. The right side shows positive cells and the gated population. 
(B) The mRNA expression levels of the sorted samples (INS, GCG, SST, PDX1, NGN3, NXK6.1, MAFA, GLP1R, 
Venus, and mCherry) with data from 3 independent experiments presented as the mean ± standard deviation 
(SD). NKX6.1: Nirenberg and Kim homeobox 6.1; MAFA: V-Maf musculoaponeurotic fibrosarcoma oncogene 
homolog a; GLP1R: glucagon-like peptide 1 receptor. *p < 0.05; **p < 0.01.
www.nature.com/scientificreports/
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High-throughput chemical screening. The hiPSC-derived INS-producing cells used in this study had no 
glucose responsivity13. In an effort to achieve glucose responsiveness and improve the efficiency of the terminal 
differentiation of β cells, we screened 90 chemicals commercially available from LOPAC Pfizer (Sigma-Aldrich) 
(Table S2), as shown in Fig. S2A. In the first quantitative high-end imaging screen using the detection of Venus+ 
INS-producing cells, we identified 9 chemicals (C3, C7, C8, C10, G11, E5, F8, H1, and H11), 6 of which inhibit 
tyrosine kinases (C3, C7, C8, C10, E5, and G11) (see Supplementary Table S2). After a second round of screen-
ing by quantitative RT-PCR analysis, we selected 3 chemicals (C3, C8, and E5) that seemed to promote β cell 
differentiation based on the expression of the endocrine markers INS, GCG, SST, GLUT2, and MAFA, which 
are critical in establishing β cell function (Fig. S2B,C). We also treated the cells with a specific inhibitor of Notch 
signalling (H1), a pathway that is indispensable for normal pancreatic development20, but this inhibitor did not 
promote differentiation. We observed quantitative reproducible findings for 4 candidates: C3, C8, E5, and H1. 
However, we concluded that the compound with the most significant efficacy in differentiating endocrine cells 
was C8 (PD166866), a specific inhibitor of FGFR1 kinase (Fig. 5A). Importantly, a third screening treatment with 
C8 alone was sufficient to significantly improve INS secretion in response to high glucose levels (Fig. 5B). This 
unexpected finding prompted us to examine whether treatment with C8 could affect the expression of functional 
β cell markers directly linked to INS secretion, as well as other markers related to β cell development and func-
tion. Strikingly, several such β cell markers, including SLC30A8 (zinc transporter), ABCC8 and chromogranin B 
(CHGB), were significantly increased by treatment with C8 (Fig. 5C). These results suggest that specific blockade 
of FGFR1 signalling promotes the intermediate and terminal differentiation of endocrine cells.
Augmentation of pancreatic endocrine cell differentiation by a specific inhibitor of 
FGFR1. Previous studies have shown that FGFR1-mediated signalling is essential for the differentiation of 
DE to PPs towards β cell maturation12,21. Indeed, most protocols for making β cells from stem cells utilize the 
FGFR1 agonists bFGF and FGF4 together with stimulation by RA to drive PDX1 expression towards the PP 
stage. Therefore, our observation that inhibition of FGFR1 signalling by C8 significantly augmented β cell lineage 
marker expression is unexpected and appears to be paradoxical. However, one possibility is that FGFR1 signalling 
promotes the early PP stage but inhibits the intermediate stage of β cell differentiation. To test this, we examined 
the effects of an FGFR1 inhibitor on the early PP stage or intermediate stage of differentiation. We treated the 
cells with C8 during the early stages, from days 3 (DE) to 10 (PPs), or during intermediate and terminal differen-
tiation, from days 10 (EPs) to 21. Intriguingly, the addition of C8 during the early stages completely inhibited the 
expression of a limited set of endocrine markers—INS, GCG, SST, PDX1, and NKX6.1, (Fig. S3A,B, [ii]). To deter-
mine if the FGFR1 signalling was responsible for the effect of C8, we evaluated the effects of shFGFR1 treatment 
at an early stage. As expected, shFGFR1 treatment downregulated PDX1 expression (Fig. S5C). To our surprise, 
the addition of the inhibitor at the intermediate-terminal stage had the opposite effect and induced a significant 
increase in endocrine markers (Fig. S3B, [i]). Thus, the appearance of a significant difference in the mode of 
FGFR1-mediated action seems to be dependent on the temporal stage of differentiation.
To better understand the effects of a blockade of FGFR1-mediated action, we verified the efficiency of β cell 
differentiation from EPs by C8 treatment using the hIveNry system (Fig. S4). Fluorescence-activated cell sort-
ing analysis showed that treatment with the inhibitor substantially increased the size of both the mCherry+ 
EP cell population and the Venus+ β cell population by 2.3-fold and 3.4-fold, respectively. This increase in cell 
population size was significantly attenuated by treatment with the FGFR1 agonist bFGF (Fig. S4B). Similarly, 
the expression of INS and PDX1 genes was substantially higher in sorted Venus+ cells treated with C8 than in 
untreated control cells (Fig. 6). Furthermore, augmentation of a series of β cell lineage markers by C8, including 
INS, PDX1, urocortin 3 (UCN3), and GCK, was specifically attenuated by the addition of the FGFR1 agonist 
bFGF (Fig. 6, C8 + bFGF). The expression levels of NKX6.1 and MAFA were not affected by treatment with C8 
and bFGF. FGF regulation of the intermediate-stage differentiation of β cells appears to be mediated selectively by 
FGFR1 since treatment with the FGFR2-specific agonist KGF did not affect the ability of C8 to increase the levels 
of β cell lineage markers (data not shown). All of our results are compatible with previous reports indicating that 
FGFR1-mediated signalling is necessary for the early differentiation of PPs. However, we made the surprising 
discovery that blockade of FGFR1 signalling robustly improves pancreatic endocrine cell differentiation at later 
stages of endocrine intermediate and terminal differentiation, indicating that FGFR1-mediated signalling has 
opposing effects on cell fate specification that are stage-dependent.
Discussion
It has been reported recently that in vitro differentiation protocols improve the maturation of pancreatic β 
cells14,15. Many studies reported that this was due to the presence of maturation factors and compared the differ-
ential expression of these factors in β cells from mice or humans that were immature or mature and either foetal 
or adult22–25. However, the molecular mechanisms of β cell differentiation remain largely unknown and protocols 
for generating β cells from stem cells in vitro have not been completely defined. In this study, we established DKI 
hiPSCs (hIveNry) that could be used to trace the differentiation status of pancreatic β cells. Using these cells, 
we discovered that inhibition of FGFR1 signalling not only promotes the intermediate stage of endocrine cell 
differentiation from EPs, but also contributes to their terminal differentiation towards mature functional β cells.
FGF signalling is indispensable for normal pancreatic development26–28. Although many studies have demon-
strated the importance of FGFR1 signalling during development, the phenotypes of mice lacking FGFR1 or its 
agonist FGF4 do not address the role of FGFR1 in endoderm formation and patterning29. Our hIveNry tracing 
model allowed us to gain molecular insights into how FGFR1-mediated signalling plays roles in each stage of 
the early- and/or intermediate-stage differentiation of β cells. We confirmed the findings of previous studies 
by demonstrating that treatment with the FGFR1 inhibitor C8 abrogates the early developing PP stage and the 
expression of PDX1 (Fig. S3). Several lines of evidence support a role for an FGFR1-PDX1 feedback loop in the 
www.nature.com/scientificreports/
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development of PPs from DE. First, the FGFR1 agonist FGF4 induces the expression of PDX1 as a target gene27. 
Second, mice expressing a dominant-negative FGFR1 driven by the PDX1 promoter become diabetic due to the 
loss of β cells and the expression of Glut28. Third, overexpression of dominant-negative PDX1 attenuates FGFR1 
expression in vivo9. Finally, ESCs lacking FGFR1 are unable to develop into pancreatic lineages30. These findings 
suggest that positive feedback regulation of the FGFR1-PDX1 cascade is essential for early β cell development 
in vitro and in vivo. In fact, the expression of PDX1 and FGFR1 is concordantly higher at the PP stage, and 
their expression profiles are correlated at each distinct stage (Fig. S5A). Moreover, this hypothesis was strongly 
Figure 5. Contribution of C8 to the maturation of functional β cells including their acquisition of glucose 
sensitivity. (A) #9–15 hIveNry cells were plated into V-bottom plates and differentiated in the same manner as 
was used in the screening assay. The cells were treated with the chemicals and screened between days 10 and 21 
of differentiation. On day 21 of differentiation, 29 to 30 clusters from each group were harvested and analysed 
for the mRNA expression levels of the endocrine markers INS, GCG, SST, PDX1, NKX6.1, and MAFA. (B) We 
tested glucose responsiveness with 30 clusters that were collected and plated into 1 well of a 24-well plate for the 
GSIS test with sequential methods. The samples were washed 3 times with PBS, pre-incubated in KRBH/2.8 M 
glucose buffer for 1 h, washed 3 times with PBS, and then incubated in low-concentration glucose (2.8 mM) 
for 1 h. After the supernatant liquid was sampled and the cells were washed twice with PBS, incubation was 
continued with high glucose (25 mM). The samples were analysed using an Ultrasensitive C-peptide ELISA kit 
(Mercodia). (C) The expression of the maturation-related markers UCN3, SLC30A8, CHGB, GLP1R, ABCC8, 
PTF1A, and GCK in 30 clusters between the control (DMSO) and C8-treated samples was assessed. Error 
bars indicate SD, n = 3. UCN3: urocortin 3; SLC30A8: solute carrier family 30 member 8; PTF1A: pancreas 
transcription factor 1A; CHGB: chromogranin B; ABCC8: ATP-binding cassette transporter sub-family C 
member 8; GCK: glucokinase; isl (islet). *p < 0.05; **p < 0.01.
www.nature.com/scientificreports/
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supported by knockdown experiments showing that shPDX1 suppresses FGFR1 expression and that shFGFR1 
suppresses PDX1 expression (Fig. S5C).
In contrast, the expression of FGFR2 appears to be lower than that of FGFR1. Therefore, it is reasonable to 
conclude that the expression of PDX1 is tied to that of FGFR1 since PDX1 is a downstream target of FGFR1. Thus, 
the FGFR1-PDX1 cascade is required to drive the transition towards the early PP and DE stages during pancreatic 
development and to establish β cell function. However, we cannot rule out the possibility that alternative signals 
are necessary for sustaining PDX1 expression in adult β cells.
Prior to this study, the role of FGFR1-mediated signalling in the intermediate NGN3+ EPs stage towards β 
cell differentiation was unknown. We showed that while FGFR1-mediated signalling is indispensable for the 
development of early-stage PPs from DE, blockade of FGFR1 at the intermediate stage of β cell differentiation is 
critical for the acceleration of efficient endocrine cell differentiation (Figs 5, 6, S3, and S4). Surprisingly to us, the 
selective augmentation of β cell differentiation by the inhibition of FGFR1-mediated signalling seems to play a 
Figure 6. C8 augments important maturation markers specifically in INS-producing β cells. Quantitative 
RT-PCR analysis was performed to measure the relative expression levels of the β cell lineage markers INS, 
UCN3, and GCK and the transcription factors PDX1, NKX6.1, and MAFA from sorted Venus+ and NC 
cells with or without treatment with C8 and/or bFGF. Briefly, #9–15 hiPSCs were differentiated as described 
above and treated with 5 μ M C8 or 5 μ M C8 and 50 ng/mL bFGF in the third stage of differentiation. After 
differentiation, samples were dissociated with TrypLE and sorted with an SH800Z cell sorter (Sony) for Venus+ 
and NC cells. Fifty cells from each group were sorted into 5 μ L FCP reagent, which is a lysate reagent of the 
QIAGEN Fast Lane cDNA kit. For cDNA synthesis, 2 μ L of the samples were used, with 0.5 μ L of the 10 μ L 
cDNA samples used for quantitative RT-PCR. Error bars indicate SD, n = 3. *p < 0.05; **p < 0.01; ***p < 0.001.
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novel and distinct role in the development of EPs. Our results are unexpected since they appear to contradict evi-
dence showing that FGFs are crucial for β cell development, as described above. Rather, the results presented here 
are consistent with previous studies and reveal distinct and opposing roles for FGFR1 signalling during early PP 
differentiation as opposed to intermediate-stage differentiation. In fact, in sorted mCherry+ EPs, the expression 
of PDX1 was diminished relative to that observed in PPs (Figs 4B, and S5A), whereas NGN3 was highly expressed 
in mCherry+ cells (Fig. S5B). This suggests that PDX1 is no longer necessary for the intermediate-stage differen-
tiation of NGN3+ EPs based on evidence of the mutually exclusive relationship between PDX1 and NGN3. This 
may partly explain why blockade of the FGFR1-PDX1 cascade contributes to the efficient β cell differentiation of 
NGN3+ EP cells. Therefore, based on our results, we hypothesize a temporal switching model in which FGFR1 
signalling drives PDX1 expression in the early stage and in mature β cells (as shown in Fig. 7). To our knowledge, 
this is the first demonstration that inhibition of FGFR1 signalling drives the augmentation of both NGN3+ EP 
cell and β cell differentiation. Indeed, this idea is clearly supported by the potentiation of Venus+ β cell (3.4-fold) 
and mCherry+ progenitor cell (2.3-fold) differentiation upon treatment with C8 and by the ablation of these 
effects in the presence of a supramaximal dose of the FGFR1 agonist bFGF (Fig. S4B). Further investigation will 
clarify the molecular mechanisms underlying the inhibitory effect of FGFR1 signalling during intermediate-stage 
differentiation towards β cell function.
Figure 7. Modelling of the proposed role of FGFR1 signalling during the early and intermediate stages of 
pancreatic β cell differentiation. Pancreatic β cells are derived from hiPSCs/ESCs via multiple differentiation 
stages including definitive endoderm (DE), pancreatic progenitor (PP), and endocrine progenitor (EP). On 
the basis of the characteristics of the expression profiles of PDX1 and NGN3 as master regulators of whole 
pancreas and hormonal EPs, respectively, β cell differentiation can be divided into at least 3 stages. First, the 
early stage is initially responsible for cell fate specification of the pancreas by the expression of PDX1 in PPs 
stimulated by FGFR1-mediated actions from DE. Second, the intermediate stage of differentiation can be 
classified as the transition from the downregulation of PDX1, prior to giving rise to NGN3-expressing EPs, to 
INS-producing cells after the loss of NGN3 expression. Third, the terminal process of β cells establishes β cell 
functions including glucose-stimulated insulin secretion (GSIS) and maintenance of glucose homeostasis by 
sustaining the expression of PDX1 in mature β cells, possibly due to the activation of FGFR1-mediated and/or 
other signals. We hypothesize that inhibition of FGFR1 signalling by C8 might promote efficient intermediate-
stage differentiation of NGN3+ EPs towards functional mature β cells. The upper panel shows the temporal 
relationships between the processes of β differentiation along with INS expression and the expression levels 
of the transcription factors NGN3 and PDX1 as downstream targets of FGFR1-mediated signalling. The 
lower panel provides a schematic representation in which the mode of intracellular FGFR1 signalling and its 
distinct status at each differentiation stage are shown. According to this representation, the mutually exclusive 
relationship between the expression of NGN3 and PDX1 depends on differentiation status and FGFR1 
signalling or its inhibition by C8.
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Although the FGFR1 agonists bFGF, FGF2, and FGF4 are necessary for early PP development to induce PDX1 
expression, FGFR1 signalling might be attenuated to facilitate transition to the NGN3+ EP stage, which is mutu-
ally exclusive with the expression of PDX1 during intermediate-stage differentiation. Regarding FGFR2-mediated 
signalling, a mouse model lacking FGF10 showed abrogation of pancreatic organogenesis and impairment of the 
maintenance and expansion of PDX1+ cells26. These results are intriguing and prompted us to determine whether 
FGFR2 signalling plays a role in the intermediate-stage differentiation of β cells. Apparently, this is not the case 
since treatment with the FGFR2 agonist KGF was unable to significantly alter the effects of C8 on endocrine 
differentiation (data not shown). In contrast, bFGF treatment attenuated β cell differentiation and the expression 
of the associated lineage markers INS, PDX1, UCN3, and GCK, strongly indicating that FGFR1 but not FGFR2 
signalling regulates the selective and specific cell fate specification of the intermediate-stage differentiation of β 
cells, possibly to drive PDX1 expression in a temporally determined, stage-specific manner (Figs 6 and S5). The 
distinct roles of FGFR1 and FGFR2 might be explained by evidence that the FGFR2 agonist FGF10 is essential for 
the proliferation of PDX1+ cells rather than for the induction of PDX1 as an initial driver26.
Tyrosine kinase inhibitors inhibit GSIS capacity31 and the majority of compounds identified by our screen 
target tyrosine kinases (Table S2). Among them, we found that treatment with C8 accelerated GSIS (Fig. 5B), pos-
sibly by increasing the levels of functional β cells due to the increased expression of functional markers, including 
SLC30A8 and ABCC8 (Fig. 5C). These results are similar to those demonstrating that the selective tyrosine kinase 
inhibitor imatinib promotes INS release from β cells32. In addition, the blockade of tyrosine kinase signalling, 
such as Src family kinases and FAK, can promote β cell differentiation33. Thus, there is growing evidence that 
tyrosine kinase signalling has a role in the differentiation of β cells as well as in maintaining the function of 
mature β cells. However, further study is needed to elucidate the roles of tyrosine kinases in this context and the 
molecular mechanisms involved.
In conclusion, we have made the unexpected discovery that specific inhibition of FGFR1 signalling at the 
intermediate stage promotes efficient later-stage (intermediate and terminal) differentiation of endocrine cells.
Materials and Methods
Construction of the INS-Venus and NGN3-mCherry bacterial artificial chromosome (BAC) 
clones and the pHDAdV INS-Venus-pGKneo and pHDAdV NGN3-mCherry-pGK-puro vec-
tors. The human BAC clones CH17-182P12 and RP11-343J3 contain the human INS and NGN3 gene loci, 
respectively, from the CH17 and RP11 Human BAC Library (BACPAC Resources, Oakland, CA, USA). The 
BAC-based targeting vector was generated as previously reported34. To construct the human INS-Venus and 
NGN3-mCherry KI constructs, the BAC clones were modified by using the RED/ET recombination technique35. 
The Venus-loxP-PGK-EM7-neo-bpA-loxP cassette was inserted into the CH17-182P12 BAC clone and the 
mCherry-loxP-PGK-EM7-neo-bpA-loxP cassette was inserted into the target site of the RP11-232J3 BAC clone. 
Subsequently, a total of 22–23 kb of homology, including the marker cassette, was sub-cloned into the HDAdV 
plasmid. A detailed description of these sub-clones will be provided on request. HDAdVs were propagated using 
293FLPe cells with the addition of the FL helper virus, as previously described36.
Cell culture. The hiPSC lines 246H1 (a gift from Dr Yamanaka at Kyoto University, Kyoto, Japan) and TIG3/
KOSM #7 were maintained as previously described37. Undifferentiated hiPSCs were maintained on a feeder layer 
of mitomycin-treated SNL76/7 cells (DS Pharma Biomedical, Osaka, Japan) in DMEM/F12 (Nacalai Tesque, 
Kyoto, Japan) supplemented with 20% Knockout-Serum Replacement (Invitrogen, Carlsbad, CA, USA), 0.1 mM 
nonessential amino acids (Wako, Osaka, Japan), 0.1 mM β -mercaptoethanol, 50 U/mL penicillin and 50 mg/mL 
streptomycin (Nacalai Tesque), and 5 ng/mL bFGF (PeproTech, Rocky Hill, NJ, USA).
Generation of the gene-targeted hiPSCs. Clumps of hiPSCs were infected with the INS-Venus HDAdV. 
Then, the hiPSCs were selected by 50 μ g/mL G418 (Nacalai Tesque) 1 day after infection. After 3 weeks, surviving 
colonies were transferred to 96-well plates and GANC selection (2 μ mol/L; Invitrogen) was started. After double 
selection, the surviving colonies were expanded and used to identify gene-targeted clones by PCR and Southern 
blotting analyses. To confirm genome-targeting events, DNA was digested with BstXl and analysed with 3 probes 
(as indicated in Fig. 1A).
For NGN3-mCherry targeting, we used INS-Venus-targeted hiPSC clone #9 after confirming that β cell differ-
entiation was induced in this clone at a higher efficiency than in the other clones. Clumps of clone #9 cells were 
infected with NGN3-mCherry HDAdV, and they were selected by 0.5 μ g/mL puromycin (InvivoGen, San Diego, 
CA, USA) 1 day after infection. After 1 week, the surviving colonies were selected with 2 μ M GANC as described 
above and then subjected to PCR and Southern blotting analyses. For the Southern blotting analyses, we digested 
the genome with AccI and AgeI (Fig. 1C, [Ac, Ag]) and analysed the digested DNA with 3 probes (as indicated in 
Fig. 1C). The dual KI hiPSCs (INS-Venus/NGN3-mCherry) (hIveNry) will be provided upon request in accord-
ance with the material transfer agreement (MTA).
Pancreatic β cell differentiation from hiPSCs. In vitro pancreatic β cell differentiation was performed 
as previously reported13 with some modifications for the chemical screening assays. Briefly, to detect the effect of 
each chemical in the screening, we omitted the chemicals (10 μ M forskolin, 5 μ M Alk5i, 10 μ M dexamethasone, 
10 mM nicotinamide) from the final stages of the original protocol. The hiPSCs were plated in a V-bottom plate 
(Thermo Fisher Scientific, Waltham, MA, USA) at 4500 cells/well in hiPSC medium without bFGF for 3 days to 
form embryoid bodies and then induced for 1 day in 100 ng/mL activin A (R&D Systems, Minneapolis, MN, USA) 
and 3 μ M CHIR (Axon Medchem, Groningen, the Netherlands). Next, the cells were induced with 100 ng/mL 
activin A for 2 days, then subjected to PP induction for 7 days with 1 μ M dorsomorphin (Wako), 2 μ M RA 
(Sigma-Aldrich), and 10 μ M SB431542 (Cayman, Ann Arbor, MI, USA). For endocrine differentiation during 
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the third stage of differentiation, we added the individual LOPAC chemicals (Sigma-Aldrich) at 5 μ M or DMSO 
for control, or the cells were fully induced with 10 μ M Fsk (Nacalai Tesque), 5 μ M Alk5 inhibitor II (Santa Cruz, 
Dallas, TX, USA), 10 μ M Dex (Sigma-Aldrich), and 10 mM Nico (Sigma-Aldrich) as a positive control.
Knockdown using a shRNA system. shRNA targeting hPDX1 and hFGFR1 were prepared by insert-
ing the following oligonucleotides into pLKO.1-puro and pLKO.1-DsRed, respectively: 5′ CCGGTGACCG 
AGAGACACAT CAACTCGAGT TGATGTGTCT CTCGGTCATT TTTG-3′ (into the target sequence reported 
as sihuPDX1 in a previous report38) and 5′ CCGGGATGGC ACCCGAGGCA TTATTCTCGA GAATAATGCC 
TCGGGTGCCA TCTTTTTG-3′ (commercially available from Sigma-Aldrich as a validated sequence). The 
viruses were prepared as previously reported39.
The hIveNry cells were infected before differentiation for 1 h in suspension and with shaking. They were then 
added to the medium and incubated for 1 day, before the medium was changed to human iPS medium. One or 
two days after, the infected hiPS cells were differentiated to PPs according to the current protocol. At day 10 or 11 
after the differentiation, 1000 DsRed-positive cells were sorted into 10 μ L FCP lysate (Qiagen) or total RNA was 
extracted from whole cells using a SV 96 kit (Promega) and subjected to quantitative real-time PCR as described 
below.
Immunostaining. The hiPSCs and differentiated cells were fixed with 4% paraformaldehyde. Expression 
of the differentiation markers was assessed using the following antibodies: goat anti-SOX17 (R&D Systems), 
guinea pig anti-INS (DAKO, Glostrup, Denmark, A0564, 1:400; or Genetex, Irvine, CA, USA, 1:100), rabbit 
anti-GCG (DAKO, 1:100), mouse anti-GCG (Sigma-Aldrich, 1:500) goat anti-SST (Santa Cruz; 1:500), mouse 
anti-C-peptide (Cell Signalling, Danvers, MA, USA, 1:1000), rabbit anti-GFP (MBL, Nagoya, Japan, 1:500), 
mouse anti-RFP (MBL, 1:1000), and sheep anti-NGN3 (R&D Systems, 1:200), rabbit anti-CHGB (Sigma-Aldrich, 
1:200). The following secondary antibodies were used: Alexa 488-conjugated goat anti-guinea pig IgG 
(Molecular Probes), CF488-conjugated donkey anti-guinea pig IgG (Biotium, Fermont, CA, USA, 1:500), Alexa 
546-conjugated goat anti-mouse IgG (Molecular Probes), Alexa 555-conjugated donkey anti-sheep IgG (Abcam, 
Cambridge, UK, ab150178, 1:500), Alexa 568-conjugated donkey anti-goat IgG (Molecular Probes, 1:300), and 
Alexa 546-conjugated anti-rabbit IgG (Molecular Probes, 1:200). Cy5-conjugated anti-rabbit IgG, Cy3-conjugated 
anti-rabbit IgG, and Cy3-conjugated anti-mouse IgG were purchased from Jackson ImmunoResearch 
Laboratories (West Grove, PA, USA). The cells were co-stained with DAPI (Sigma-Aldrich). The samples were 
visualized using Leica TCS SP8 confocal microscope, Zeiss Axiovert 200 M microscope (Zeiss) and Keyence 
BZ-X700 fluorescence microscope (Keyence).
Quantitative real-time PCR. RNA was extracted using an SV RNA kit and SV96 kit (Promega, Madison, 
WI, USA). For cDNA synthesis, we used ReverTra Ace qPCR RT Master Mix with gDNA Remover (TOYOBO, 
Osaka, Japan) and analysed the results with Gene Ace SYBR qPCR Mix (Nippon Gene, Tokyo, Japan) on a Light 
Cycler 480 thermal cycler (Roche, Basel, Switzerland). The expression level of each gene was normalised to that 
of GAPDH using the delta-delta CT method and expressed as arbitrary units. The primers used are listed in 
Supplementary Table S1. For the sorted samples, we also used a FastLane Cell cDNA kit (Qiagen, Dusseldorf, 
Germany). We sorted 50 target cells in each tube containing 5 μ L FCP lysis buffer and, after following the manu-
facturer’s protocol to remove genomic DNA, performed the reverse transcription procedure. Real-time PCR was 
performed using the Gene Ace SYBR qPCR mix.
C-peptide release assay. Differentiated hiPSCs were washed 3 times with phosphate-buffered saline (PBS) 
and pre-incubated with KRBH containing 2.8 mM glucose for 1 h. The cells were washed 3 times with PBS and 
incubated with low glucose (2.8 mM)/KRBH buffer for 1 h. Finally, the cells were incubated with high glucose 
(25 mM)/KRBH buffer for 1 h. INS secretion into the culture medium was measured with a Human Ultrasensitive 
C-peptide ELISA kit (Mercodia, Uppsala, Sweden).
High-end imaging analysis. In the screening assay, differentiated cells in a V-bottom plate were stained 
with Hoechst 33342 (Molecular Probes). This signal was imaged, together with Venus and mCherry fluores-
cence via BGRFR_386, BGRFR_485 and BGRFR_549 filters, respectively, using a 5x objective and the same expo-
sure time in all plates in an ArrayScan system (Thermo Fisher Scientific) running HCS scan software and the 
CellHealth profiling algorithm protocol.
Flow cytometry. The differentiated cells were dissociated with Accutase (Nacalai Tesque). The number of 
Venus- and mCherry-expressing cells was analysed in an SH800Z cell sorter (Sony, Tokyo, Japan). The Venus+ 
cells, mCherry+ cells, and negative cells were sorted for mRNA expression analysis by excluding dead cells with 
7AAD and doublet cells with a FSC-H/FSC-W chart.
Statistical analysis. Statistical analysis was performed using paired t-tests. Differences between groups were 
considered significant for values of p < 0.05.
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